SARS-CoV-2 Mpro-IN-2

SARS-CoV-2 Mpro-IN-2 is a selective SARS-CoV-2M pro inhibitor with an IC50 value of 0.40 μM.SARS-CoV-2 Mpro-IN-2 has good antiviral activity and can be used to study COVID-19.

SARS-CoV-2/MERS Mpro-IN-2 is a potent inhibitor of the main proteases of SARS-CoV-2 and MERS, with IC50 values of 0.21 and 0.07 µM, respectively.

SARS-CoV-2 Mpro-IN-25 (Compound 3a) is a protease inhibitor for SARS-CoV-2, exhibiting an IC50 value of 0.26 μM. It demonstrates antiviral activity and is useful for research in the field of pneumonia.

SARS-CoV-2 Mpro-IN-26 (compound 13) is a covalent inhibitor targeting SARS-CoV-2 Mpro.

SARS-CoV-2 Mpro-IN-27 (Compound 4h) is an effective inhibitor of SARS-CoV-2 Mpro.

SARS-CoV-2 Mpro-IN-29 (Compound 7) is an inhibitor of the SARS-CoV-2 main protease (Mpro), with an IC50 of 310 nM for Mpro and an EC50 of 0.5 μM in Vero cells. By binding to the active site of Mpro, it prevents the cleavage of viral polyproteins, exhibiting significant antiviral activity and enhanced metabolic properties. SARS-CoV-2 Mpro-IN-29 holds potential for research in SARS-CoV-2 antiviral drug development.

SARS-CoV-2 Mpro-IN-24 (Compound X77) is an inhibitor of SARS-CoV-2 Mpro with an IC50 value of 2.8 μM and acts as a non-covalent inhibitor of SARS-CoV Mpro with an IC50 value of 3.4 μM.

SARS-CoV-2 Mpro-IN-20 (compound MPI100) is an inhibitor of the main protease of SARS-CoV-2. It exhibits antiviral activity with an EC50 value of 3.4 μM.

SARS-CoV-2 Mpro-IN-21 (compound A8) is an effective inhibitor of the SARS-CoV-2 and COVID-19 Main Protease MPro. It demonstrates significant antioxidant activity in the DPPH assay with an IC50 of 0.36 mg/mL. SARS-CoV-2 Mpro-IN-21 also shows notable antibacterial activity against Klebsiella, with an IC50 of 1.19 mg/mL.

SARS-CoV-2 Mpro-IN-23 (Compound 2) is an inhibitor of the SARS-CoV-2 main protease (Mpro), effective against both wild-type and mutant Mpro variants with an IC50 range of 0.057-0.92 μM. It also disrupts the late-stage entry of wild-type SARS-CoV-2 single-round infectious particles (SRIP) and inhibits viral replication of both the Mpro wild-type and its mutants, with an EC50 range of 0.02-0.52 μM.

SARS-CoV-2 Mpro-IN-22 (compound 4) is an effective inhibitor of the SARS-CoV-2 main protease (Mpro), with an IC50 of 1.2 µg/mL. This hydrolyzable tannin exhibits no significant cytotoxic activity in A549 and HUVEC cell lines.

SARS-CoV-2 Mpro-IN-28 (Compound 1K) is an inhibitor of SARS-CoV-2 Mpro, exhibiting an EC50 of 24 μM.

SARS-CoV-2 Mpro-IN-9 (compound c7), a nonpeptidic, noncovalent inhibitor of SARS-CoV-2 main protease (Mpro), exhibits potent inhibitory action (IC50 = 0.085 μM) and improved physicochemical and drug metabolism and pharmacokinetics (DMPK) properties. It effectively suppresses viral replication in SARS-CoV-2-infected Vero E6 cells (EC50 = 1.10 μM) and demonstrates low cytotoxicity (CC50 > 50 μM) [1].

SARS-CoV-2-IN-1 is a potent inhibitor of Mpro [SARS-CoV-2 Mpro, SARS-CoV Mpro, and MERS-CoV Mpro] with IC50 values of 0.67, 0.90, and 0.58 μM, respectively.

GC373, an effective inhibitor of the SARS-CoV-2 M pro, impedes virus replication, exhibiting an inhibition concentration (IC 50) of 0.4 μM. This compound is valuable for use in anti-COVID-19 research.

SARS-CoV-2 Mpro-IN-31 (Compound 18) is an inhibitor of SARS-CoV-2 MPro with an IC50 of 11 nM. Additionally, this compound effectively inhibits the enzymatic activity of the cysteine proteases cathepsin B and cathepsin L, with IC50 values of 24 nM and 1.8 nM, respectively.

ZINC4497834 is an inhibitor of the main protease Mpro of SARS-CoV-2. It is utilized in research targeting the treatment of COVID-19.

SARS-CoV-2 Mpro-IN-32 (Compound 1) is a selective inhibitor of SARS-CoV-2 MPro with an IC50 value of 230 nM. In vitro, it also inhibits the replication of various SARS-CoV-2 variants.

SARS-CoV-2 Mpro-IN-34 (Compound 26) acts as an inhibitor of SARS-CoV-2 Mpro with an IC50 of 6 nM. It also inhibits OC43 Mpro, demonstrating an IC50 of 33 nM. Furthermore, this compound exhibits antiviral activity in Vero E6 cells infected with SARS-CoV-2, with an EC50 of 0.103 μM.

Mpro inhibitor 818 is a novel fragment-like inhibitor targeting the main protease of SARS-CoV-2, demonstrating antiviral activity in vitro.

Mpro Inhibitor 737 is a novel fragment-based inhibitor targeting the main protease of SARS-CoV-2. It has demonstrated antiviral activity in in vitro models.

H117 is a PROTAC target protein ligand that can be used in the synthesis of PROTAC HP211206. It competitively binds to and inhibits the main protease (Mpro) of SARS-CoV-2, with an IC50 of 151.3 nM.

NZ-804 is an orally active inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 of 8.9 nM. It inhibits replication of SARS-CoV-2 in HeLa-hACE2 cells, showing an EC50 of 14 nM. NZ-804 exhibits broad-spectrum antiviral activity against various CoVs and decreases viral replication in mice and hamster models.

SARS-CoV-2 Mpro-IN-35 (compound 14) is an inhibitor of SARS-CoV-2 Mpro and is applicable in the study of the SARS-CoV-2 virus.